ESMO Media Releases

Third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016

The award will be presented at the European Lung Cancer Conference (ELCC) 2016, held 13 to 16 April in Geneva, Switzerland.

The latest article to appear on ESMO Open highlights ESMO’s hope that the 2015 WHO Model List of Essential Medicines (EML) will empower oncologists and advocates to demand routine availability of the medicines considered essential to guarantee quality care of cancer patients

Creation of CMO role reflects ESMO’s rapid growth and follows extensive six-month selection process

On World Cancer Day, ESMO puts cancer patients centre stage by organising a workshop dedicated to exploring ways that advocacy networks can drive research

ESMO announces the appointment of Keith Hanson McGregor as their new CEO. Dr McGregor is currently ESMO’s Chief Operating Officer.

KEYNOTE-010 data further supports broadening pembrolizumab availability for all advanced NSCLC patients with PD-L1 expression over 1%

LUX-Lung 7 trial reveals that the second-generation EGFR tyrosine kinase inhibitor significantly improved PFS in naive patients with advanced mutated lung cancer compared to gefitinib

Promising results of PALOMA3 trial confirmed in Asian patients

Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer.  Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study

Underprivileged patients are at major risk of disease-related “financial catastrophe", study in eight low- and middle-income Southeast Asian countries shows

LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.